Financials
- Fiscal year
- 2025
- Total assets
- €1.9m
- Loss
- -€3,205
- Solvency
- 1.8%
Total assets▼ 2.1%
Net result
20182025
2PHARMA HOLDING
ActiveSummary
2PHARMA HOLDING has been active since 2015 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €34,480 and a net result of -€3,205. Equity is shrinking by ~8.3% per year across the filed fiscal years. The computed 12-month bankruptcy probability is 1.0% (low).
Overview
What they do
Activity not known
How big
€1.9mtotal assets 2025
- Equity
- €34,480
- Loss
- -€3,205
Who decides
- Parent
- Ceres Pharma · 100%
- Board
- 3 members
- Holdings
- 1
Accounts 1 d early1 of 6 deeds read
Why 64- Liquidity: current ratio 0.00- No establishment unit in the KBO+ Size: total assets €1.9m+ No main activity registeredShow the evidence
Checked score
Score 2025
64
/ 100
Healthy
Probability in this band: 0.55% to 1.5%
Better than 18% of its sector peers (no NACE code, micro)
Performance against the sector, not lower risk
Financial strength · tick = 2024
Weak
Solvency
27=
equity 1.8% of total assets
Liquidity
0=
short-term debt 98.2%
Profitability
37=
return on assets -0.2%
Bankruptcy probability, 12 months
1.0%
Low
0%0.5%1.5%4%10%≥ 25%
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 4 months
07-2026: 1.4%highest value
08-2026: 0.9%▼ -35.5% vs 07-2026lowest value
09-2026: 1.0%▲ +13.2% vs 08-2026
10-2026: 1.0%● 0.0% vs 09-2026
- Liquidity: current ratio 0.00 raises the probability
- Size: total assets €1.9m lowers the probability for this profile
- No establishment unit in the KBO raises the probability
- No main activity registered lowers the probability
Credit up to €2,000 at 30 days acceptable
Liquidity short (current ratio 0.0 against 0.02 in 2024; short-term debt: 98.2% of total assets), and 98.2% of the assets are financed with debt.
How it is calculated
The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (no NACE code, micro). Better than this share of them on solvency 17%, liquidity 1%, profitability 28%, growth against the median 26%. That is performance, not lower risk; the band itself always comes from the probability.
Bankruptcy probability: model pd-v3.202610021621, computed on 02-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.
Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025Net result per financial year
1819202122232425
2018 to 2025 · latest year -€3,205
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-07-2026, 1 day ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
1 d early
2024
1 d early
2023
6 d early
2022
31 d late
2021
20 d early
2020
19 d early
2019
25 d late
← before the deadline
after the deadline →
tick = median of all Belgian filings
This company filed its last 7 accounts on average 1 day after the deadline; the Belgian median for financial year 2024 is 4 days before the deadline, and 38% of all filings were late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 30 July (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
02-10-2026 today31-12-2026 close31-07-2027 deadline
- Annual accounts filedfiscal year 2025 · full…
- Permanent representatives: DEBEL Mario, IMSCHOOT Anja…Resignations: MD CONSULT, AQUITANIA and…
- Annual accounts filedfiscal year 2024 · abbreviated…
Key points
By topic
Board & ownership
- Board
- 3 members
- Parent
- Ceres Pharma · 100%
Go to Board & ownership
Network & group
- Group
- Ceres Invest
- Subsidiaries
- 1
- Connected companies
- 1
1 subsidiary
Timeline
- Events
- 12
- Since
- 2017
- Next accounts
- by 31-07-2027
- 30-07-2026Annual accounts filed
- 29-04-2026Permanent representatives: DEBEL Mario, IMSCHOOT Anja and…
- 30-07-2025Annual accounts filed
Company details
- Legal form
- Public limited company
- Founded
- 22-12-2015
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Articles of association
- Provisions read
- 48
- Who signs
- Each director alone
- Purpose
- 1. het beleggen, het intekenen op, vast overnemen, plaatsen, kopen, verkopen en…
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check Which other companies belong to the same group?Ceres Invest · 12 companies How does this company compare with its sector?Sector benchmark
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.